Regulatory officials have granted Molbreevi priority review and assigned a goal date of Aug. 22, 2026. If approved, Molbreevi will be priced between $400,000 and $500,000 per year.

Savara Inc. (Nasdaq: SVRA) (the Company), a clinical-stage biopharmaceutical company focused on rare respiratory diseases, ...

Air pollution cannot be eliminated by individual effort alone, but exposure can be reduced and lung injury can be slowed. Protecting lung health today depends on consistent, realistic choices rather ...

Scientific literature provides evidence that the way we breathe influences neural areas related to attention, memory, smell, ...

Amidst rising pollution and pandemic concerns, maintaining lung health is crucial. The article highlights effective lung detox methods, including specific pranayama breathing exercises like Rechaka ...

Covid-19 is not just a respiratory infection. Cardiovascular symptoms are seen in both acute and long covid. Katharine Lang reports on what we’ve learnt since the onset of the pandemic Cardiovascular ...

An 18-month-old baby held with her parents at a South Texas immigration detention center became so ill last month that she was rushed to a hospital with life-threatening respiratory failure — then ...